Download PDF
Thromb Haemost 1976; 35(02): 386-395
DOI: 10.1055/s-0038-1647933
Original Article
Schattauer GmbH

Various Prothrombin Complex Concentrates and their Effect on Coagulation and Fibrinolysis In Vivo

U Hedner
1   Coagulation Laboratory, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
,
I.M Nilsson
1   Coagulation Laboratory, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
,
S.-E Bergentz
1   Coagulation Laboratory, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
› Author Affiliations
Further Information

Publication History

Received 24 October 1975

Accepted 20 November 1975

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

Summary

Thromboembolic complications occurring in patients treated with factor IX concentrates have been reported. To study the thrombogenicity various types of factor IX concentrates (50 or 100 units F. IX/kg bodyweight) have been infused in dogs. As control albumin was given. The various components of the coagulation and fibrinolytic system have been assayed before the infusion and at various intervals after the end of infusion (0, 1,4 and 24 hrs). Konyne resulted in marked activation of the coagulation process with decrease of platelets, fibrinogen, F. VIII and appearance of FDP and positive ethanol gelation test. Pro thro mplex and Pre-conativ gave no significant changes. Preconativ is prepared without addition of heparin during the procedure.

 

  • References

  • 1 Biggs R. 1970. Clinical experience with factor IX concentrate of Bidwell. In: Brinkhous K. M. (Ed.). Hemophilia and New Hemorrhagic States, International Symposium, New York . The University of North Carolina Press; Chapel Hill: p 31.
    Google Scholar
  • 2 Blatt P. M, Lundblad R. L, Kingdon H. S, McLean G, Roberts H. R. 1974; Thrombogenic materials in prothrombin complex concentrates. Annals of Internal Medicine 81: 766.
    CrossrefPubMedGoogle Scholar
  • 3 Breen Jr. F. A, Tullis J. L. 1969; Prothrombin concentrates in treatment of Christmas disease and allied disorders. The Journal of the American Medical Association 208: 1853.
    CrossrefPubMedGoogle Scholar
  • 4 Cash J. D, Dalton R. G, Middleton S, Smith J. K. 1975; Studies on the thrombogenicity of Scottish factor IX concentrates in dogs. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 33: 632.
    PubMedGoogle Scholar
  • 5 Cederbaum A. I, Roberts H. R. 1973; Complications of the use of prothrombin complex concentrates in liver disease. Clinical Research 21: 92.
    PubMedGoogle Scholar
  • 6 Deyktn D, Wessler S. 1964; Activation product, factor IX, serum thrombotic accelerator activity, and serum-induced thrombosis. Journal of Clinical Investigation 43: 160.
    CrossrefPubMedGoogle Scholar
  • 7 Edson J. R. 1974; Prothrombin-complex concentrates and thrombosis. New England Journal of Medicine 290: 403.
    CrossrefPubMedGoogle Scholar
  • 8 Fagerhol M. K, Abildgaard U. 1970; Immunological studies on human antithrombin III. Influence of age, sex and use of oral contraceptives on serum concentration. Scandinavian Journal of Haematology 7: 10.
    PubMedGoogle Scholar
  • 9 Ganrot P. O. 1966; Determination of α2-macroglobulin as trypsinprotein esterase. Clinica Chimica Acta 14: 493.
    CrossrefPubMedGoogle Scholar
  • 10 Godal H. C, Abildgaard U, Kierulf P. 1971; Ethanol gelation and fibrin monomers in plasma. Scandinavian Journal of Haemotology, Suppl 13: 189.
    PubMedGoogle Scholar
  • 11 Grammens G. L, Breckenridge R. T. 1974; Complications with Christmas factor (factor IX) concentrates. Annals of Internal Medicine 80: 666.
    CrossrefPubMedGoogle Scholar
  • 12 Kasper C. K. 1973; Postoperative thrombosis in hemophilia B. New England Journal of Medicine 289: 160.
    PubMedGoogle Scholar
  • 13 Kasper C. K. 1975; Thromboembolic complications. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 33: 640.
    PubMedGoogle Scholar
  • 14 King J. B, Fitzgerald L. D. 1975 Platelet count in original plasma in relation to thrombogenicity of factor IX concentrate. XIV Congress of the International Society of Blood Transfusion, X Congress of the World Federation of Hemophilia, Helsinki, Finland July 27 - August 1. .
    PubMedGoogle Scholar
  • 15 Kingdon H. S, Lundblad R. L, Veltkamp J. J, Aronson D. L. 1975; Potentially thrombogenic materials in factor IX concentrates. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 33: 617.
    PubMedGoogle Scholar
  • 16 Latallo Z. S, Wegrzynowicz E, Teisseyre E, Kopeć M. 1970; Simple and rapid evaluation of the intravascular coagulation and fibrinolytic status by application of protamine sulphate and Reptilase. Scandinavian Journal of Haematology, Suppl 13: 387.
    PubMedGoogle Scholar
  • 17 Leandoer L, Bergentz S.-E, Nilsson I. M. 1968; Coagulation factors and components of the fibrinolytic system in lymph and blood in dogs. Thrombosis et Diathesis Haemorrhagica 19: 129.
    PubMedGoogle Scholar
  • 18 Marchesi S. L, Burney R. 1974; Prothrombin-complex concentrates and thrombosis. New England Journal of Medicine 290: 403.
    CrossrefPubMedGoogle Scholar
  • 19 Ménaché D. 1975; Factor IX concentrates. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 33: 600.
    PubMedGoogle Scholar
  • 20 Ménaché D, Guillin M. C. 1975; The use of factor IX concentrates for patients with conditions other than factor IX deficiency. British Journal of Haemotology 31 (Suppl), 247.
    PubMedGoogle Scholar
  • 21 Niléhn J.-E. 1967; Separation and estimation of “split products” of fibrinogen and fibrin in human serum. Thrombosis et Diathesis Haemorrhagica 18: 487.
    PubMedGoogle Scholar
  • 22 Nilsson I. M. 1974. Haemorrhagic and Thrombotic Diseases. John Wiley & Sons; London:
    Google Scholar
  • 23 Nilsson I. M, Ahlberg Å, Björlin G. 1971; Clinical experience with a Swedish factor IX concentrate. Acta medica scandinavica 190: 257.
    PubMedGoogle Scholar
  • 24 Nilsson I. M, Blombäck M, Ramgren O. 1961; Haemophilia in Sweden. I. Coagulation studies. Acta medica scandinavica 170: 665.
    PubMedGoogle Scholar
  • 25 Nilsson I. M, Olow B. 1962; Determination of fibrinogen and fibrinogenolytic activity. Thrombosis et Diathesis Haemorrhagica 8: 297.
    PubMedGoogle Scholar
  • 26 Paraskevas M, Nilsson I. M, Martinsson G. 1962; A method for determining serum inhibitors of plasminogen activation. Scandinavian Journal of Clinical and Laboratory Investigation 14: 138.
    CrossrefPubMedGoogle Scholar
  • 27 Soulier J. P, Ménaché D, Steinbach M, Blatrix C. H, Josso F. 1969; Preparation and clinical use of P.P.S.B, (factors II, VII, X and IX concentrates). Thrombosis et Diathesis Haemorrhagica, Suppl 35: 61.
    PubMedGoogle Scholar
  • 28 Steinberg M. H, Dreiling B. J. 1974; Vascular lesions in hemophilia B. New England Journal of Medicine 289: 592.
    PubMedGoogle Scholar
  • 29 Tullis J. L, Melin M, Jurgian P. 1965; Clinical use of human prothrombin complexes. New England Journal of Medicine 273: 667.
    CrossrefPubMedGoogle Scholar